<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain><z:hpo ids='HP_0005110'>Atrial fibrillation</z:hpo> is a common <z:hpo ids='HP_0011675'>arrhythmia</z:hpo> that increases the risk of <z:hpo ids='HP_0001297'>stroke</z:hpo> and <z:mpath ids='MPATH_118'>systemic embolism</z:mpath> </plain></SENT>
<SENT sid="1" pm="."><plain><z:chebi fb="8" ids="10033">Warfarin</z:chebi> is a highly effective treatment in reducing this risk, but a narrow therapeutic range, drug and food interactions, required monitoring, and <z:mp ids='MP_0001914'>bleeding</z:mp> limit its use </plain></SENT>
<SENT sid="2" pm="."><plain>We review Apixaban, an oral inhibitor of Factor Xa, which has been shown in large randomized trials to have superior efficacy in <z:hpo ids='HP_0001297'>stroke</z:hpo> reduction without an excess in <z:mp ids='MP_0001914'>bleeding</z:mp> events when compared with aspirin in those deemed unsuitable to receive <z:chebi fb="8" ids="10033">warfarin</z:chebi>, and demonstrates superior efficacy in reducing <z:hpo ids='HP_0001297'>stroke</z:hpo> and <z:mpath ids='MPATH_118'>systemic embolism</z:mpath> in addition to a reduction in <z:mp ids='MP_0001914'>bleeding</z:mp> events when compared to <z:chebi fb="8" ids="10033">warfarin</z:chebi> </plain></SENT>
</text></document>